secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0000950170-23-036766
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin Q2 revenue $80M (-15%); net loss narrows to $17.6M; lowers 2023 opex guidance
--------------------------------------------------------------------------------

- Total net revenue $80.2M (-15% YoY); net product revenue $65.2M (-31% YoY) due to generic competition.
- GAAP net loss $17.6M ($0.04 loss per share) vs $70.0M loss ($0.18 loss) in Q2 2022; non-GAAP adjusted net income $8.6M.
- Cash and investments $313M; generated positive cash flow of $9M during the quarter.
- Lowering 2023 operating expense guidance to $240-250M from $270-285M; cost reduction plan savings $40M over 12 months.
- Spain's drug pricing committee recommended national reimbursement of VAZKEPA; regulatory approvals in China and Saudi Arabia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000095017023036766/0000950170-23-036766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000095017023036766/amrn-20230802.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-036766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer